{
    "clinical_study": {
        "@rank": "6519", 
        "acronym": "PANTHER", 
        "arm_group": {
            "arm_group_label": "AZD8931 + FOLFIRI", 
            "arm_group_type": "Experimental", 
            "description": "AZD8931 (20, 40, 80 or 160 mg bd on days 1 - 4) in combination with FOLFIRI starting on day 1 of every 2-weekly cycle: Irinotecan 180 mg/m2 IV infusion, Folinic acid 350 mg IV infusion, Fluorouracil 400 mg/m2 IV bolus, Fluorouracil 2400 mg/m2 IV continuous infusion over 46 hours."
        }, 
        "brief_summary": {
            "textblock": "In phase I, the aim of the study is to determine the recommended phase II dose of AZD8931 in\n      combination with standard chemotherapy, FOLFIRI, by assessing the safety and tolerability of\n      the combination treatment.\n\n      In phase II, the combination of AZD8931 and FOLFIRI will be compared to FOLFIRI alone, to\n      determine the efficacy of the treatment."
        }, 
        "brief_title": "Phase I/II Trial of Antagonism of HER in GI Cancer", 
        "completion_date": {
            "#text": "August 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Metastatic Colorectal Cancer", 
            "Recurrent Colorectal Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "PANTHER is a registered phase I/randomised phase II trial in patients with recurrent or\n      metastatic colorectal cancer. Patients are recruited to received AZD8931 (an EGFR/ERBB\n      inhibitor) in combination with FOLinic acid, Fluorouracil and IRInotecan (FOLFIRI). AZD8931\n      and FOLFIRI will be given in two-weekly cycles. The Phase I trial will aim to determine the\n      recommended Phase II dose of AZD8931 (either 20, 40, 80 or 160mg bd, on days 1-4 of each\n      2-weekly cycle) - the dose of AZD8931 that patients will receive will depend on the dose\n      under investigation at the time of registration.\n\n      The AZD8931 dose will be determined by the Modified Continual Reassessment Method (mCRM).\n      mCRM is a dose-toxicity model which describes the probability of a toxicity occurring at\n      each dose level, which is based on clinical judgment and any available toxicity data.\n\n      The recommended AZD8931 dose in combination with FOLFIRI, determined from the phase I trial,\n      will become one of the treatment groups in the randomised Phase II - the other treatment\n      group will be FOLFIRI alone (Control group)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histopathological/cytological diagnosis of non-resectable, recurrent or metastatic\n             colorectal cancer\n\n          2. Tumour with wild-type KRAS\n\n          3. Measurable disease evaluated by RECIST criteria v1.1\n\n          4. WHO performance status 0 or 1\n\n          5. Age \u2265 18\n\n          6. Estimated life expectancy > 3 months\n\n          7. Adequate haematological function:\n\n               -  Haemoglobin \u2265100 g/L\n\n               -  WBC \u22653.0 x 10^9/L\n\n               -  Absolute neutrophil count \u22651.5 x 10^9/L\n\n               -  Platelet count \u2265100 x 10^9/L\n\n          8. Adequate liver function:\n\n               -  Total bilirubin \u22641.5 x upper limit of normal (ULN)\n\n               -  ALT, AST & ALP \u22642.5 x ULN in the absence of noted liver metastases\n\n               -  ALT, AST & ALP \u22645 x ULN in the presence of liver metastases\n\n          9. Adequate renal function:\n\n               -  Serum creatinine \u22641.5 x ULN\n\n               -  Calculated creatinine clearance \u226530 mL/min\n\n         10. Adequate biliary drainage (patients with stents are eligible)\n\n         11. Adequate venous access for collection of exploratory biological samples\n\n         12. Women of child-bearing potential must have a negative pregnancy test prior to study\n             entry. Female patients and male patients with partners of child-bearing potential\n             must agree to use an adequate contraception method, which must be continued for 6\n             months after completion of chemotherapy\n\n         13. Must be able to swallow AZD8931 tablets\n\n         14. Capable of giving written informed consent\n\n         15. The following prior therapy is allowed:\n\n               -  Surgery - patients may have undergone a non-curative operation or palliative\n                  bypass surgery only. Patients who have previously undergone curative surgery\n                  must have evidence of non-resectable disease relapse\n\n               -  Radiotherapy - for localised disease\n\n               -  Prior adjuvant chemotherapy - provided this was completed at least 6 months\n                  before trial entry\n\n        Exclusion Criteria:\n\n          1. Patients undergoing treatment with curative intent\n\n          2. Any prior treatment with agents targeting the ERBB pathway\n\n          3. Treatment with experimental drugs within 30 days or 5 half-lives of first dose of\n             AZD8931\n\n          4. Previous chemotherapy for metastatic disease\n\n          5. Prior treatment with anthracyclines or mitoxantrone\n\n          6. Current disease or condition known to interfere with absorption, distribution,\n             metabolism or excretion of drugs (including refractory nausea and vomiting, chronic\n             gastrointestinal disease (e.g. inflammatory bowel disease), or significant bowel\n             resection)\n\n          7. History of prior malignancy that will interfere with the response evaluation\n             (exceptions listed in protocol)\n\n          8. Evidence of severe/uncontrolled systemic diseases or laboratory finding that makes it\n             undesirable for the patient to participate in the trial\n\n          9. Evidence of active uncontrolled infection\n\n         10. Patients with clinically significant ascites and/or effusions\n\n         11. Regular use of anti-diarrhoeal\n\n         12. Pregnant or lactating women\n\n         13. Cardiac conditions (as detailed in the trial protocol)\n\n         14. Any psychiatric or other disorder (e.g. brain metastases) likely to impact the\n             ability to give informed consent\n\n         15. Eye conditions (as detailed in the trial protocol)\n\n         16. Patients with chronic skin conditions e.g. acne rosacea, psoriasis, severe atopic\n             eczema\n\n         17. Past medical history of interstitial lung disease, drug-induced interstitial lung\n             disease, radiation pneumonitis which required steroid treatment, or any evidence of\n             clinically active interstitial lung disease\n\n         18. History or repeated unexplained episodes of syncope/dizziness\n\n         19. Known hypersensitivity to AZD8931, its excipients, or drugs in its class\n\n         20. The use of drugs/substances known to inhibit or induce CYP3A4 or CYP2D6, or those\n             known to prolong QT interval, which cannot be discontinued for the duration of trial\n             treatment\n\n         21. Patients with hereditary fructose intolerance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01862003", 
            "org_study_id": "UCL/12/0136"
        }, 
        "intervention": [
            {
                "arm_group_label": "AZD8931 + FOLFIRI", 
                "description": "20, 40, 80 or 160 mg AZD8931 tablets, twice daily on days 1 - 4 of each 2-weekly cycle", 
                "intervention_name": "AZD8931", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "AZD8931 + FOLFIRI", 
                "description": "180 mg/m2 (IV infusion) of Irinotecan on day 1 of each 2-weekly cycle - can be given simultaneously with Folinic acid.", 
                "intervention_name": "Irinotecan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "AZD8931 + FOLFIRI", 
                "description": "350 mg (IV infusion) of Folinic acid on day 1 of each 2-weekly cycle - can be given simultaneously with Irinotecan.", 
                "intervention_name": "Folinic Acid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "AZD8931 + FOLFIRI", 
                "description": "400 mg/m2 (IV bolus) of Fluorouracil on day 1 of each 2-weekly cycle, to be given after completion of Irinotecan and Folinic acid.", 
                "intervention_name": "Fluorouracil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "AZD8931 + FOLFIRI", 
                "description": "2400 mg/m2 (IV) continuous infusion of Fluorouracil given over 46 hours - infusion to start after 5FU bolus.", 
                "intervention_name": "Fluorouracil", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Irinotecan", 
                "Leucovorin", 
                "Folic Acid", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Colorectal cancer", 
            "Metastatic Colorectal cancer", 
            "Recurrent Colorectal cancer", 
            "FOLFIRI", 
            "AZD8931", 
            "Chemotherapy", 
            "EGFR"
        ], 
        "lastchanged_date": "May 21, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "University College London Hospital NHS Foundation Trust"
                }, 
                "investigator": {
                    "last_name": "Daniel Hochhauser", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Guy's and St Thomas' NHS Foundation Trust"
                }, 
                "investigator": {
                    "last_name": "Debashis Sarker", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Barts Health NHS Trust"
                }, 
                "investigator": {
                    "last_name": "David Propper", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }, 
                    "name": "The Christie NHS Foundation Trust"
                }, 
                "investigator": {
                    "last_name": "Mark Saunders", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "AZD8931, an Inhibitor of EGFR, ERBB2 and ERBB3 Signalling, in Combination With FOLFIRI: a Phase I/II Study to Determine the Importance of Schedule and Activity in Colorectal Cancer", 
        "overall_contact": {
            "email": "ctc.panther@ucl.ac.uk", 
            "last_name": "Rubina Begum", 
            "phone": "020 7679 9514"
        }, 
        "overall_contact_backup": {
            "email": "ctc.panther@ucl.ac.uk", 
            "last_name": "Sharon Forsyth", 
            "phone": "020 7679 9264"
        }, 
        "overall_official": {
            "affiliation": "University College London (UCL) Cancer Institute", 
            "last_name": "Daniel Hochhauser, BA, MBBS, MRCP, D.PHIL, FRCP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United Kingdom: National Health Service", 
                "United Kingdom: National Institute for Health Research", 
                "United Kingdom: Research Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Detailed adverse event monitoring will be conducted according to CTCAE v4.03. Dose Limiting Toxicity (DLT) is defined as any adverse event or laboratory abnormality detailed in the trial protocol, that is considered to be related to AZD8931 and commencing anytime during the DLT evaluation period (from start of cycle 1 to end of cycle 1). Adverse Events include: Skin, Gastrointestinal, Haematological, Clinical Chemistry, Cardiovascular.", 
            "measure": "Occurrence of Dose Limiting Toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "From start of cycle 1 to end of cycle 1 (each cycle = 2 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01862003"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PK analysis of plasma AZD8931, irinotecan and metabolite concentrations. Blood samples (plasma) will be taken on the following days: Pre-treatment (before any trial related treatment), AZD8931 alone Day 1, Cycle 1 Day 1, Cycle 1 Day 2, Cycle 2 Day 1, Cycle 2 Day 2.", 
                "measure": "Measurement of Pharmacokinetic parameters (AUC, Cmax, t1/2) of AZD8931, Irinotecan and metabolite concentrations", 
                "safety_issue": "No", 
                "time_frame": "PK parameters taken - pre-dose, 1.5, 2 or 2.5, 4, 8 & 10 hrs post AZD8931 dose or after starting irinotecan - measurements taken pre-FOLFIRI, cycle 1 day 1 & cycle 2 day 1; pre-AZD8931 dose on cycle 1 day 2 & cycle 2 day 2"
            }, 
            {
                "description": "A sum of the diameters for all target lesions will be calculated according to RECIST v1.1. The difference between the baseline sum of diameters and the week 12 sum will be the change in tumour size at 12 weeks after the start of chemotherapy.", 
                "measure": "Change in tumour size from baseline at 12 weeks using RECIST v1.1", 
                "safety_issue": "No", 
                "time_frame": "Baseline CT scan compared to CT scan taken 12 weeks after start of combination chemotherapy"
            }, 
            {
                "description": "Best overall response will be assessed according to RECIST v1.1. Confirmation of complete or partial response is not required. Stable disease will be considered the best response only if a second assessment has been carried out which confirms SD at least four weeks after trial entry. Assessment will be determined using CT scans performed at baseline, 12 weeks after start of chemotherapy, then every 3 months until disease progression up to 3 years from registration", 
                "measure": "Best overall response", 
                "safety_issue": "No", 
                "time_frame": "Determined using CT scans performed at baseline (registration), 12 weeks after start of chemotherapy, then every 3 months until disease progression up to 3 years from date of registration"
            }, 
            {
                "description": "Progression-free survival time will be calculated from the date of trial entry to the date of documented progression, or death from any cause. In cases where progression is suspected and subsequently confirmed by scans, the date of documented suspected progression will be used.", 
                "measure": "Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "From date of registration to date of documented disease progression or death from any cause, whichever comes first, assessed up to 3 years from date of registration"
            }, 
            {
                "description": "Overall survival time will be calculated from the date of trial entry to the date of death from any cause or end of trial follow-up.", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "From date of registration until date of death or date of last follow-up assessment (up to 3 years from date of registration)"
            }, 
            {
                "description": "Will include all grade 1-5 adverse events", 
                "measure": "Occurrence and Severity of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "From date of registration until 30 days after completion of trial treatment (AZD8931 and FOLFIRI)"
            }
        ], 
        "source": "University College, London", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Cancer Research UK", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "AstraZeneca", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "UCL Biomedical Research Centre", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University College, London", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}